欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的观察穿膜融合多肽TAT—N24对急性T细胞白血病Jurkat细胞增殖的影响。方法以穿膜融合多肽TAT．N24处理Jurkat细胞，噻唑蓝（MTT）法观察细胞的生长情况，应用流式细胞仪检测Jurkat细胞周期进程。结果穿膜融合多肽TAT—N24处理急性T细胞白血病Jurkat细胞48h，细胞生长受到抑制，随着多肽浓度的增加，抑制作用增强，表现出明显的浓度依赖性（P〈0．05）；48h后细胞生长明显受抑，并随时间延长生长受抑更加明显，表现出时间依赖性（P〈0．05）。空白对照组Jurkat细胞中G0／G1期细胞数为（41．91±1．96）％，s期和G2／M期细胞数分别为（52．16±1．76）％和（5．93±0．30）％；对照多肽组Jurkat细胞中C0／G1期细胞数为（46．38±2．31）％，s期和G2／M期细胞数分别为（44．22±1．69）％和（9．40±0．98）％；TAT—N24组Jurkat细胞中G0／G1期细胞数为（54．83±1．92）％，s期和G2／M期细胞数分别为（30．75±2．27）％和（14．42±0．68）％。结论融合多肽TAT—N24可以有效抑制急性T细胞白血病Jurkat细胞的增殖，阻滞其周期进程。
英文摘要：
Objective To elucidate the inhibitory effect of cell-permeable TAT-N24 fusion peptide on Jurkat cell. Methods Jurkat cells were treated with cell-permeable TAT-N24. The cell growth was detected by MTI＂ method and the cell cycle progression determined by flow cytometer. Results TAT-N24 inhibited the cells in concentration- and time-dependent manners. The survival rate of cells exposed to TAT-N24 was lower than that of the control group after 48 h. The higher the concentration of TAT-N24,the lower the survival rate of the cells （P〈0.05）. The growth rate of the cells exposed to TAT-N24 began to decrease after 48 h, and this effect was significantly time-dependent （P〈0.05）. Cell cycle analysis revealed that the proportion of ceils in G0/G1, S and G2/M phases was （41.91 ±1.96） %, （52.16±1.76） % and （5.93±0.30） % respectively in the control group and was （46.38±2.31）%, （44.22_±1.69）%, （9.40±0.98）% respectively in the control peptide group. However in the TAT-N24 group, the proportion of cells in G0/G1, S and GJM phases was （54.83±1.92）%, （30.75±2.27）% and （14.42±0.68） % respectively. Conclusion TAT-N24 fusion peptide can restrain the growth of Jurka and induce the cell cycle arrest.
同期刊论文项目
同项目期刊论文
Jing Wang, Weicheng Liu, Feng Lv, et al. Blocking p55PIK limits Lipopolysaccharide-induced activatio
Guihua Wang, Xiaonian Cao, Senyan Lai, et al. Altered p53 regulation of miR-148b and p55PIK contribu
期刊信息
位置：